1.15

2.68% 0.03

After Hours: 1.14 -0.01 -0.87%

Telomir Pharmaceuticals Inc (TELO)

Overview News Price History Discussions Forecast

Telomir Pharmaceuticals Inc stock is traded at $1.15, with a volume of 119.37K. It is up +2.68% in the last 24 hours and down -20.69% over the past month. Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.

Previous Close:

$1.12

Open:

$1.11

24h Volume:

119.37K

Relative Volume:

0.35

Market Cap:

$39.54M

Revenue:

Net Income/Loss:

$-16.14M

P/E Ratio:

-2.1296

EPS:

-0.54

Net Cash Flow:

$-3.99M

1W Performance:

+0.88%

1M Performance:

-20.69%

6M Performance:

-37.50%

1Y Performance:

-74.56%

1-Day Range:

$1.11

$1.19

1-Week Range:

$1.07

$1.2399

52-Week Range:

$1.07

$5.40

Telomir Pharmaceuticals Inc Stock (TELO) Company Profile

Name

Telomir Pharmaceuticals Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

786-396-6723

Address

100 SE 2ND ST, MIAMI

Employee

Twitter

Next Earnings Date

2025-12-03

Latest SEC Filings

TELO's Discussions on Twitter

Compare TELO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TELO Telomir Pharmaceuticals Inc	1.15	38.51M	0	-16.14M	-3.99M	-0.54
VRTX Vertex Pharmaceuticals Inc	477.92	116.41B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	785.51	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	811.45	50.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	328.16	43.76B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	353.92	38.40B	4.98B	69.60M	525.67M	0.5198

Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-21-25	Initiated	Rodman & Renshaw	Buy

Telomir Pharmaceuticals Inc Stock (TELO) Latest News

Feb 05, 2026

What are the risks of holding Telomir Pharmaceuticals IncChart Signals & Daily Growth Stock Investment Tips - baoquankhu1.vn

Feb 05, 2026

Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging - accessnewswire.com

Feb 05, 2026

Telomir Pharmaceuticals Highlights Preclinical Data for Telomir-1 - TipRanks

Feb 05, 2026

Experimental Telomir-Zn compound rebalances metals tied to cancer and aging - stocktitan.net

Feb 05, 2026

Telomir Pharmaceuticals Reports New Cellular Data on Epigenetic Modulation - TradingView

Feb 05, 2026

Feb 02, 2026

Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - Hillsdale Daily News

Feb 02, 2026

Jan 31, 2026

Setup Watch: Can Telomir Pharmaceuticals Inc outperform under higher oil pricesJuly 2025 Selloffs & Expert Approved Momentum Trade Ideas - baoquankhu1.vn

Jan 31, 2026

US Market Wrap: Is SIGA in a consolidation phasePortfolio Update Summary & Low Drawdown Investment Strategies - baoquankhu1.vn

Jan 31, 2026

Jan 30, 2026